A5240

A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1 Infected Females.

Who Can Enroll: Female with no history of ASCUS Pap or cryo for Abnl pap. Several study arms. Study team is screening for pts.

Study Therapy: Gardasil vaccine provided by study.

Study RN: Please contact Elizabeth Lindsey at 205-996-5165.

 

A5247

A phase 2 Study to evaluate Safety, tolerability and immunogenicity of ZOSTAVAX (Zoster Vaccine Live) in HIV patients on HAART with conserved Immune Function.

Who Can Enroll: History of Varicella or herpes zoster >1year prior to study entry OR VZV seropositive anytime prior to entry. VL<75 CD4 > 200 no H/O CD4 <100.

Study Therapy: ZOSTAVAX (Zoster Vaccine Live) vs Placebo

Study RN: Please contact Elizabeth Lindsey at 205-996-5165.

 

Valtrex HSV-2 study

Seroprevalence of HSV-2 in HIV-infected Subjects and the Effect of Daily Valacyclovir in the Reduction of HSV-2 Recurrences and Viral Shedding.

Who Can Enroll: Must be taking a failing PI-containing regimen for at least 8 weeks. Provides resistance test. VL >1000 Any CD4.

Study Therapy: Valtrex 1 gm. vs placebo Daily for suppression. Meds provided by study.

Study RN: Please contact Suzette Byars at 205-975-9127.

 

GFR Study

Evaluation of the Performance of GFR Estimating Equations In HIV Positive Patients.

Who Can Enroll: Males and females on HAART. Excludes current or prior peritoneal dialysis or hemodialysis within 3 months. No VL or CD4 requirement Must be on HAART.

Study Therapy: Three study visits. This study will compare GFR measured by the plasma clearance of iohexol (a urinary filtration marker) to serum creatinine and cystatin C based GFR estimating equations among HIV positive patients.

Study RN: Please contact Karen Savage at 205-975-7925.